
Product Data Sheet

Product Name: KC02
Cat. No.: GC13023

Chemical Properties

Cas. No. 1646795-60-9

Chemical Name 6-(2-oxo-4-tridecyloxetan-3-yl)hexanamide

SMILES CCCCCCCCCCCCC1OC(C1CCCCC(N)=O)=O

Formula $C_{22}H_{41}NO_3$ M.Wt 367.57

Solubility DMF: 5 mg/ml, DMSO: 5 mg/ml, Ethanol: 16 mg/ml, Ethanol: PBS (pH 7.2) (1:5): 0.5 mg/ml
Store
Storage at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

Background

KC02 is a structural analog of KC01 and inactive form of KC01.

The synthesis of KC02 consistently yielded a 4:1 mixture of Z/E isomers, which proved difficult to chromatographically separate. By competitive gel-based ABPP assays, KC02 inhibited ABHD16A (human and mouse) with IC₅₀ value of >10 μM, while KC01 is in range of nM. By PS substrate assays, KC02 inhibited human ABHD16A with IC₅₀ value of > 10 μM, while KC01 is in range of nM.

Most of these enzymes were also inhibited by the control probe KC02, with the exception of two partial off-targets, ABHD3 and ABHD13. KC02 also inhibited ABHD11 (94%) and LYPLA1 (63%) but did not substantially inhibit ABHD16A (<30%). In situ treatment with KC01 (1 μM, 4 h) but not KC02 (1 μM, 4 h) blocked the PS lipase activity of membrane fractions from COLO205, K562 and MCF7 cell lines. KC01 and KC02 constitute a suitable pair of active and inactive (control) probes to investigate the function of

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

ABHD16A in cellular systems. Treatment with KC01 but not KC02 (1 μ M, 4 h) substantially lowered secreted lyso-PSs of the ABHD12-null LCL. All LCLs also showed decreased cellular lyso-PSs following treatment with KC01 but not KC02. KC01 but not KC02 elevated PS lipase activity and reduced in lyso-PS lipase activity in LPS-stimulated macrophages. The LPS-induced increases in lyso-PS and cytokine secretion were both blocked by pretreatment of Abhd12 $-/-$ macrophages with KC01 (1 μ M, 4 h) but not KC02 (1 μ M, 4 h).

In COLO205 cells, 1 μ M KC01 but not KC02 showed substantial reductions in the levels of all detected cellular lyso-PSs compared to DMSO-treated control cells. The levels of secreted lyso-PSs (18:1 and 18:0) were also decreased in COLO205 cells treated with KC01 compared to those in KC02- or DMSO-treated cells (4-h treatments of cells in serum-free medium), whereas levels of other secreted lipids (lyso-PCs, lyso-PEs and MAGs) were unchanged across these treatment groups.

KC01, but not KC02, inhibited the PS lipase activity of brain membrane lysates from 2-month-old Abhd12 $+/+$ and Abhd12 $-/-$ mice.

Reference:

1. Kamat SS, Camara K2, Parsons WH et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. *Nat Chem Biol.* 2015 Feb;11(2):164-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA
